Erratum: Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling (Clinical Cancer Research (2016) 22 (1531-1544) DOI: 10.1158/1078-0432.CCR-15-1632);Flightless i homolog represses prostate cancer progression through targeting androgen receptor signaling

Clinical Cancer Research

Volumn 22, Issue 6, 2016, Pages 1531-1544

  Wang, Tao ^a   Song, Wen ^a   Chen, Yuan ^a   Chen, Ruibao ^a   Liu, Zhuo ^a   Wu, Licheng ^a   Li, Mingchao ^a   Yang, Jun ^a   Wang, Liang ^a   Liu, Jihong ^a   Ye, Zhangqun ^a   Wang, Chenguang ^b   Chen, Ke ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; ENZALUTAMIDE; FLIGHTLESS I PROTEIN; GELSOLIN; KI 67 ANTIGEN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CELL RECEPTOR; FLII PROTEIN, HUMAN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLII GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; LIGAND BINDING; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; RECEPTOR BLOCKING; STABLE EXPRESSION; TRANSACTIVATION; CHEMISTRY; DISEASE COURSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84962315500     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-22-1796     Document Type: Erratum

References (50)

1. Alberti C. Prostate cancer progression and surrounding microenvironment. Int J Biol Markers 2006;21:88-95.
2. Wang T, Liu Z, Guo S, Wu L, Li M, Yang J, et al. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget 2014;5: 3611-21.
3. Sung YY, Cheung E. Androgen receptor co-regulatory networks in castration-resistant prostate cancer. Endocr Relat Cancer 2013;21:R1-R11.
4. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
5. Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephrourol Mon 2013;5:792-800.
6. Saad F, Fizazi KS. Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration resistant prostate cancer. Urology. 2015 Aug 14. [Epub ahead of print].
7. Greasley R, Khabazhaitajer M, Rosario DJ. A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Manag Res 2015;12:153-64.
8. Modena A, Ciccarese C, Fantinel E, Bimbatti D, Tortora G, Massari F. Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther 2015;15:1037-48.
9. Xu S, Wang T, Song W, Jiang T, Zhang F, Yin Y, et al. The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism. Sci Rep 2015;5:13528.
10. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007;120: 719-33.
11. Vasaitis TS, Njar VC. Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments. Future Med Chem 2010;2:667-80.
12. Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother 2015;16: 1521-37.
13. Li J, Yin HL, Yuan J. Flightless-I regulates proinflammatory caspases by selectively modulating intracellular localization and caspase activity. J Cell Biol 2008;181:321-33.
14. Archer SK, Behm CA, Claudianos C, Campbell HD. The flightless I protein and the gelsolin family in nuclear hormone receptor-mediated signalling. Biochem Soc Trans 2004;32:940-2.
15. Wu L, Chen H, Zhu Y, Meng J, Li Y, Li M, et al. Flightless I homolog negatively regulates ChREBP activity in cancer cells. Int J Biochem Cell Biol 2013;45:2688-97.
16. Jeong KW, Lee YH, Stallcup MR. Recruitment of the SWI/SNF chromatin remodeling complex to steroid hormone-regulated promoters by nuclear receptor coactivator flightless-I. J Biol Chem 2009;284:29298-309.
17. Jeong KW. Flightless I (Drosophila) homolog facilitates chromatin accessibility of the estrogen receptor a target genes in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2014;446:608-13.
18. Choi JS, Choi SS, Kim ES, Seo YK, Seo JK, Kim EK, et al. Flightless-1, a novel transcriptional modulator of PPARg through competing with RXRa. Cell Signal 2015;27:614-20
19. Lee YH, Stallcup MR. Interplay of Fli-I and FLAP1 for regulation of betacatenin dependent transcription. Nucleic Acids Res 2006;34:5052-9.
20. Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 2012;287:8571-83.
21. Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 2004;279:32444-52.
22. Wang T, Guo S, Liu Z, Wu L, Li M, Yang J, et al. CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget 2014;5:10293-306.
23. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
24. Chen K, Wu K, Cai S, Zhang W, Zhou J, Wang J, et al. Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer Res 2013;73: 3262-74.
25. Wu K, Chen K, Wang C, Jiao X, Wang L, Zhou J, et al. Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. Cancer Res 2014;74:829-39.
26. Chen K, Wu K, Gormley M, Ertel A, Wang J, Zhang W, et al. Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer. Oncotarget 2013;4:923-35.
27. Connor KM, Hempel N, Nelson KK, Dabiri G, Gamarra A, Belarmino J, et al. Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res 2007;67:10260-7.
28. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov 2013;3:1302-15
29. Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe Y, et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 2007;5:383-91.
30. Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 2010;12:639-57.
31. Li H, Ren X, Leblanc E, Frewin K, Rennie PS, Cherkasov A. Identification of novel androgen receptor antagonists using structure- and ligand-based methods. J Chem Inf Model 2013;53:123-30.
32. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002;277:26321-6.
33. Lakshmikanthan V, Zou L, Kim JI, Michal A, Nie Z, Messias NC, et al. Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci U S A 2009;106:9379-84.
34. Kang HY, Yeh S, Fujimoto N, Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 1999;274:8570-6.
35. Poukka H, Karvonen U, Yoshikawa N, Tanaka H, Palvimo JJ, Jünne OA. The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci 2000;113:2991-3001.
36. Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007;67:8388-95.
37. Devlin HL, Mudryj M. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 2009;274:177-86.
38. Stan SD, Singh SV. Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells. Clin Cancer Res 2009;15:4895-4903.
39. Qu F, Cui X, Hong Y, Wang J, Li Y, Chen L, et al. MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor. Mol Cell Biochem 2013;377:121-30.
40. Nacusi LP, Tindall DJ. Androgen receptor abnormalities in castrationrecurrent prostate cancer. Expert Rev Endocrinol Metab 2009;4:417-22.
41. Dehm SM, Tindall DJ. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem 2006;281: 27882-93.
42. Zhang Y, Yang Y, Yeh S, Chang C. ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol Cell Biol 2004;24: 1044-57.
43. Felgueiras J, Silva JV, Fardilha M. Prostate cancer: the need for biomarkers and new therapeutic targets. J Zhejiang Univ Sci B 2014;15:16-42.
44. Cui J, Yang Y, Zhang C, Hu P, Kan W, Bai X, et al. FBI-1 functions as a novel AR co-repressor in prostate cancer cells. Cell Mol Life Sci 2011;68: 1091-103.
45. Kang HY, Tsai MY, Chang C, Huang KE. Mechanisms and clinical relevance of androgens and androgen receptor actions. Chang Gung Med J 2003;26: 388-402.
46. Trtkova K, Paskova L, Matijescukova N, Strnad M, Kolar Z. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB. Neoplasma 2010;57:406-14.
47. Guenther MG, Barak O, Lazar MA. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 2001;21: 6091-101.
48. Lee YH, Campbell HD, Stallcup MR. Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity. Mol Cell Biol 2004;24:2103-17.
49. Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 2014;5:265-73.
50. Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, et al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res 2015;75: 3663-71.